MIRA Pharmaceuticals Inc. $(MIRA)$ has announced significant progress in its regulatory journey with the U.S. Securities and Exchange Commission $(SEC.UK)$ finalizing its review of the merger proxy related to MIRA's acquisition of SKNY Pharmaceuticals. With no comments from the SEC, MIRA is now moving toward shareholder approval and the final steps needed to complete the transaction. This acquisition includes SKNY-1, an investigational therapy targeting obesity and nicotine addiction. Additionally, MIRA's proprietary drug candidate, Mira-55, has shown promising preclinical results, matching morphine in pain relief without opioid risks, and has received confirmation from the U.S. Drug Enforcement Administration $(DEA)$ that it is not a controlled substance, facilitating further clinical development.